RBC Bioscience

RBC Bioscience Working Capital

Working Capital of RBC Bioscience (6848.TWO) as of Oct 17, 2026.

Working Capital

0.00TWD

Last updated:

Working Capital of RBC Bioscience is 2025 0.00 TWD. Working Capital of RBC Bioscience was 2024 21.07 M TWD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RBC Bioscience Stock analysis

What does RBC Bioscience do? RBC Bioscience Corp, based in Taipei, Taiwan, operates in the Health Care sector within the Life Sciences Tools & Services industry. The company manufactures reagents and devices for life science and molecular diagnosis, including instruments with ultraviolet sterilization systems and disposable reagent strips for nucleic acid extraction. Its products, featuring cellulose-embedded magnetic beads, purify DNA and RNA from various sources for diagnostic and forensic applications. Listed on 25 October 2021, RBC Bioscience serves markets requiring advanced molecular analysis tools. RBC Bioscience is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RBC Bioscience stock

On Eulerpool you can find the complete historical development of Working Capital RBC Bioscience since 2006 – with annual values, charts, and detailed analysis.

Working capital is the difference between current assets and current liabilities. Positive working capital indicates a company can meet its short-term obligations.

Working Capital's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Working Capital's RBC Bioscience historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — RBC Bioscience

All Key Metrics — RBC Bioscience